GC
RCKT icon

GMT Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

GMT Capital’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-188,100
Closed -$4.05M – 77
2024
Q2 		$4.05M Sell
188,100
-41,900
-18% -$962K 0.15% 38
2024
Q1 		$6.2M Sell
230,000
-76,500
-25% -$2.17M 0.24% 31
2023
Q4 		$9.19M Sell
306,500
-104,700
-25% -$2.31M 0.35% 35
2023
Q3 		$8.43M Sell
411,200
-20,900
-5% -$380K 0.32% 45
2023
Q2 		$8.59M Sell
432,100
-74,000
-15% -$1.5M 0.32% 42
2023
Q1 		$8.67M Buy
506,100
+134,800
+36% +$2.64M 0.34% 41
2022
Q4 		$7.27M Hold
371,300
– – 0.34% 45
2022
Q3 		$5.93M Sell
371,300
-125,500
-25% -$1.96M 0.37% 47
2022
Q2 		$6.84M Buy
+496,800
New +$5.92M 0.43% 43

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

GMT Capital's RCKT Position: Q3 2024 in Review

GMT Capital sold out of Rocket Pharmaceuticals (RCKT) in Q3 2024, closing a stake of 188,100 shares — an estimated $4.05M sold.

GMT Capital first reported a position in RCKT in Q2 2022 and held it in 9 quarters. The position peaked at $9.19M in Q4 2023. 191 funds tracked by Wall St. Rank hold RCKT as of Q3 2024.

  • GMT Capital reported no remaining Rocket Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • GMT Capital sold 188,100 Rocket Pharmaceuticals shares in Q3 2024, an estimated $4.05M.
  • GMT Capital first reported a position in Rocket Pharmaceuticals in Q2 2022 and held it in 9 quarters.
  • GMT Capital's Rocket Pharmaceuticals position peaked at $9.19M in Q4 2023.
  • 191 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2024.

Based on GMT Capital's 13F filing for Q3 2024, filed 14 Nov 2024.